Filter By Category
Archives
Share on -
APITOLISIB
Generic Name: APITOLISIB
ABSTRACT -
Apitolisib is an oral small-molecule inhibitor of PI3K and mTOR signaling.
It has been investigated in oncology for tumors driven by PI3K/AKT/mTOR pathway activation.
It is not approved for routine clinical use.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- No approved standard dosing regimen is established for this API.
- Doses, route, premedication, monitoring, and dose modifications must follow the applicable clinical-trial or specialist protocol.
- Do not use outside an approved study, compassionate-use program, or authorized regulatory setting.
SIDE EFFECTS–
- Possible side effects may include:
- Hyperglycemia
- Rash
- Diarrhea
- Mucositis or stomatitis
- Nausea
- Fatigue
- Decreased appetite
- Pneumonitis risk
- Liver enzyme abnormalities
ALLERGIC REACTIONS -
- Hypersensitivity to the active compound or excipients is possible.
- Symptoms may include skin rash, urticaria, pruritus, facial swelling, wheezing, dizziness, or anaphylaxis.
- Patients with a suspected allergic reaction should stop treatment and seek urgent medical attention.
DRUG INTERACTIONS–
- Strong CYP inhibitors or inducers may alter exposure depending on metabolism.
- Antidiabetic medicines may require adjustment if hyperglycemia occurs.
- Other anticancer agents may add myelosuppression, rash, mucositis, or GI toxicity.
PREAUTIONS–
- Monitor glucose, liver enzymes, blood counts, and pulmonary symptoms.
- Use caution in diabetes, uncontrolled infection, or interstitial lung disease.
- Avoid pregnancy due to potential fetal harm.
- Manage rash and diarrhea early.
WARNINGS –
- PI3K/mTOR inhibitors can cause severe hyperglycemia, rash, diarrhea, pneumonitis, and infection.
- Investigational agent only.
- Use only under oncology supervision.
Share on -
. Developed by